TA

Takeda

Every trial this sponsor leads in the registry, and everything it has published.

1,405All trials
Recruiting56
Recruited22
Not yet recruiting5
Completed1,110
Stopped212

83 active · 6% of this sponsor’s registry footprint

Oncology24 trials
Immunology & Inflammation22 trials
Neurology9 trials
Haematology7 trials
Dermatology5 trials
Infectious Disease5 trials
Gastroenterology & Hepatology2 trials
Metabolic/Endocrine/Nutrition1 trial

Not shown above: 6 trials whose condition matched no therapy area.

Trials by phase

Phase 1422
Phase 2318
Phase 3530
Phase 4123
Unphased12

Pipeline by phase · 32 drugs in active development

Phase 3 · 17 drugs

Zasocitinib (TAK-279)12 trials · 9 recruitingest. Feb 2027
Elritercept (TAK-226)6 trials · 6 recruitingest. Feb 2028
Mezagitamab4 trials · 3 recruitingest. Mar 2028
Fazirsiran Injection3 trials · 2 recruitingest. Aug 2028
Mobocertinib (TAK-788)3 trialsest. Oct 2026
Tetravalent Dengue Vaccine3 trials · 2 recruitingest. Apr 2027
Maribavir2 trials · 2 recruitingest. Dec 2026
Oveporexton (TAK-861)2 trials · 1 recruitingest. Oct 2026

Phase 2 · 5 drugs

TAK-3604 trials · 4 recruitingest. Nov 2026
Rusfertide2 trials · 1 recruitingest. Oct 2027
Idursulfase-IT1 trialest. Jan 2029
Sitocabnagene Loxiveleucel (TAK-007)1 trial
TAK-4111 trial · 1 recruitingest. Dec 2027

Phase 1 · 5 drugs

AskBio0091 trialest. Jan 2030
TAK-1881 trial · 1 recruitingest. Dec 2028
TAK-5051 trial · 1 recruitingest. Aug 2030
TAK-7811 trial · 1 recruitingest. Apr 2028
TAK-8531 trial

Phase 4 · 5 drugs

Vedolizumab12 trials · 10 recruitingest. Jun 2027
Brentuximab vedotin3 trials · 1 recruitingest. Mar 2028
CDPATH™1 trial
Fruquintinib1 trial · 1 recruitingest. Oct 2027
Replagal1 trial · 1 recruitingest. Oct 2027

Not counted above: 2 unphased interventions.

Active trials only, code names and brands merged. 1,110 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 3 of 10 curated

Non-small cell lung cancer (Oncology)3 trials · 1 drug0.2% of landscape
Ulcerative colitis (Gastroenterology & Hepatology)2 trials · 1 recruiting · 2 drugs1.2% of landscape
Multiple myeloma (Oncology)1 trial · 1 recruiting · 1 drug0.1% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon